Become A Featured Company

Tetra Bio-Pharma: First Clinical Trial of Natural Cannabis for Cancer Pain Entering Phase III

Ryan Allway

June 8th, 2017

News, Top News

Medical cannabis has gained widespread acceptance throughout North America, but many physicians are still hesitant to prescribe the drug without evidence from clinical trials. While many companies are developing synthetic drugs based on cannabinoids, there are some companies that remain committed to realizing the synergistic capabilities of the whole cannabis plant and proving its therapeutic benefit.

In this article, we will look at Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: TBPMF) and its recent progress in bringing its smokable marijuana therapeutic to market.

Smokeable Cannabis Trial

Tetra Bio-Pharma’s PPP001 is the first smokeable cannabis drug product being developed for the treatment of pain in late-stage cancer patients. According to Global Pain Management, approximately 50% of cancer patients suffer from pain and more than 600,000 of these patients suffer from moderate-to-severe pain. The overall market for pain-related therapeutics is valued at over $5 billion with over four million cancer patients in the United States alone.

If approved by the FDA, the company’s PPP001 will be sold as a titanium pipe and blister pack containing drug pellets with a standardized amount of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). A single drug pellet is pushed out of the blister pack, inserted into the titanium pipe, and smoked to deliver the active ingredients. Management anticipates securing marketing approval in Canada and the United States by early 2019.

The development of PPP001 will confirm the efficacy of smoked cannabis in treating underlying medical conditions and essentially validate the use of medical marijuana. At the same time, patients would be able to access the ‘raw’ form of the drug (as opposed to synthetic versions) with a prescription that may be covered by health insurance. These dynamics could make medical cannabis much more affordable for patients and credible in the eyes of doctors.

Making Significant Strides

Tetra Bio-Pharma recently announced the completion of its Phase I safety and pharmacokinetics report for PPP001 and its submission to Health Canada. The data demonstrated that the inhalation of PPP001 achieved the targeted plasma level of THC that could potentially achieve pain relief in cancer patients without the use of opioids. The company will continue to complete the research needed to ensure that the drug conforms to regulatory requirements.

“Shareholders should be proud to know how quickly we have moved through the Phase I trial and we are now progressing on an accelerated path to the Phase III trial which is, relatively speaking, a tremendous accomplishment for the organization and a testament of the excellent work undertaken by Dr. Chamberland and his team,” said Tetra Bio-Pharma CEO Andre Rancourt in the press release announcing the news.

The company simultaneously announced preparation for a Phase III clinical trial in collaboration with Quebec’s leading medical cannabis clinic, Sante Cannabis. Management anticipates that the new clinical trial will be launched by the fourth quarter of this year or the first quarter of next year. In May, the company met with Health Canada and received feedback and guidance on this critical trial and its plans to secure approvals for PPP001.

Looking Ahead

Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: TBPMF) represents a compelling investment opportunity within the cannabis industry. With its PPP001 program, the completion of Phase I clinical trials and the preparation for Phase III clinical trials marks an important milestone for the company and its shareholders. Investors may want to keep a close eye on the company as it gears up to advance these trials and bring the first smokeable cannabis to market.

In addition to PPP001, the company has several other clinical programs in its pipeline that could generate incremental shareholder value. PPP002 is a Dronabinol-based mucoadhesive wafer designed to manage anorexia and cancer chemotherapy-related pain; PPP003 is a combination product targeting chronic pain, PTSD, and other conditions; PTGR is a topical prescription drug for pain management; and, AGT001 is another topical product for pain management.

For more information, visit the company’s website at www.tetrabiopharma.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading